Free shipping on all orders over $ 500

SB 216763

Cat. No. M2061
SB 216763 Structure
Size Price Availability Quantity
5mg USD 50  USD50 In stock
10mg USD 80  USD80 In stock
50mg USD 240  USD240 In stock
100mg USD 430  USD430 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SB 216763 is a potent and selective ATP-competitive inhibitor of the serine/threonine protein kinase glycogen synthase kinase-3 (GSK-3) α and β isozymes. Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase that is inhibited by an assortment of extracellular stimuli including insulin, growth factors, cell specification factors, and cell adhesion. SB 216763 displays similar potency for GSK-3β with 96% inhibition at 10 μM while exhibiting minimal activity against 24 other protein kinases (IC50 >10 μM). SB 216763 stimulates glycogen synthesis in Chang human liver cells with an EC50 value of 3.6 µM and induces expression of a β-catenin-LEF/TCF regulated reporter gene in HEK293 cells. SB 216763 treatment at 25-50 μM reduces cell viability in a dose-dependent manner, and leads to significant increase in apoptosis by 50% at 72 hours due to the specific down regulation of GSK-3β. Administration of SB 216763 at 20 mg/kg significantly prevents lung inflammation and the subsequent fibrosis in bleomycin (BLM)-induced pulmonary inflammation and fibrosis model in mice by significantly blocking the production of inflammatory cytokines MCP-1 and TNF-α by macrophages.

Customer Product Validations & Biological Datas
Source PLoS One (2012). Figure 1. SB 216763
Method dual luciferase reporter activity
Cell Lines HEK293 cells
Concentrations 10 μM
Incubation Time 24 h
Results "As expected, HEK293 cells treated with 1–20 μM SB-216763 exhibited a dose-dependent increase in Super TOPFlash activity"
Protocol (for reference only)
Cell Experiment
Cell lines BXPC-3 cells and MIA-PaCa2 cells
Preparation method BXPC-3 cells were treated with DMSO or the indicated concentration of GSK-3β inhibitors (AR-A014418 and SB216763) over the indicated time course. Relative cell viability was measured using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. B, MIA-PaCa2 cells and the normal human mammary epithelial cell line HMEC, and embryonic lung fibroblast cell line WI38 were treated with DMSO or the indicated GSK-3β inhibitor (25 μmol/L).
Concentrations 1, 10, 25, 50µM
Incubation time 24, 48 or 72h
Animal Experiment
Animal models saline induced pulmonary fibrosis model of C57BL/6N mice (12 weeks old)
Formulation 25% dimethyl sulfoxide, 25% polyethylene glycol, and 50% saline
Dosages 20 mg/kg
Administration intravenously twice a week until day 28
Chemical Information
Molecular Weight 371.22
Formula C19H12Cl2N2O2
CAS Number 280744-09-4
Solubility (25°C) DMSO 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Kirby LA, et al. PLoS One. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells.

[2] Coghlan MP, et al. Chem Biol. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Related GSK-3 Products
Phospho-Glycogen Synthase Peptide-2(substrate)

Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases.

FRATtide

FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and β-catenin.

ZDWX-25

ZDWX-25 is a highly potent GSK-3β and DYRK1A dual inhibitor with an IC50 value of 71 nM for GSK-3β.

TC-G 24

TC-G 24 is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 17.1 nM.

SAR502250

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β.

  Catalog
Abmole Inhibitor Catalog




Keywords: SB 216763 supplier, GSK-3, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.